TrialMolecular cancer2025

Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).

Xi-Yu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.